Targeting antibody-mediated complement-independent mechanism in bullous pemphigoid with diacerein
Bullous pemphigoid (BP) is an antibody-mediated blistering disease predominantly affecting the elderly. The pathogenesis involves both complement-dependent and complement-independent mechanisms. The therapeutic potential of targeting complement-independent mechanism has not yet been determined. The mainstay of treatment, corticosteroid, has many side effects, indicating the needs of better treatments. (Source: Journal of Dermatological Science)
Source: Journal of Dermatological Science - March 5, 2024 Category: Dermatology Authors: Yung-Tsu Cho, Chih-Hung Lee, Jing-Yi Lee, Chia-Yu Chu Tags: Original Article Source Type: research
Study Design of a Phase 2/3 Randomized Controlled Trial of Dupilumab in Adults with Bullous Pemphigoid: LIBERTY-BP ADEPT
ConclusionThe trial results will provide evidence on whether the efficacy and safety of dupilumab support its use as a potential novel treatment approach for BP and will provide new insights into the role of type 2 inflammation in BP pathogenesis.Clinical Trial RegistrationClinicalTrials.gov identifier NCT04206553. (Source: Advances in Therapy)
Source: Advances in Therapy - March 5, 2024 Category: Drugs & Pharmacology Source Type: research
Epidemiology and Co-Morbidities of Mucous Membrane Pemphigoid: A National Cohort Study
Mucous membrane pemphigoid (MMP) is a chronic, progressive, and often scarring sub-epidermal autoimmune blistering disease predominantly affecting mucous membranes. Autoantibodies in MMP target multiple antigens including BP180, BP230, laminin 332, collagen VII, and the integrin α6 and β4 subunits (Rashid et al., 2021). The incidence of MMP has been estimated varying from 1.3 to 2.0/million/year. It is more common in females and usually diagnosed between 60 and 80 years of age (Du et al., 2022). (Source: Journal of Investigative Dermatology)
Source: Journal of Investigative Dermatology - March 3, 2024 Category: Dermatology Authors: P äivi Leisti, Laura Huilaja, Jari Jokelainen, Outi Varpuluoma, Kaisa Tasanen Tags: Letters to the Editor Source Type: research
Epidemiology and Comorbidities of Mucous Membrane Pemphigoid: A National Cohort Study
Mucous membrane pemphigoid (MMP) is a chronic, progressive, and often scarring subepidermal autoimmune blistering disease predominantly affecting mucous membranes. Autoantibodies in MMP target multiple antigens, including BP180, BP230, laminin 332, collagen VII, and the integrin α6 and β4 subunits (Rashid et al, 2021). The incidence of MMP has been estimated, varying from 1.3 to 2.0 per million per year. It is more common in females and is usually diagnosed between the ages of 60 and 80 years (Du et al, 2022). (Source: Journal of Investigative Dermatology)
Source: Journal of Investigative Dermatology - March 3, 2024 Category: Dermatology Authors: P äivi Leisti, Laura Huilaja, Jari Jokelainen, Outi Varpuluoma, Kaisa Tasanen Tags: Letters to the Editor Source Type: research
Real-Time Experience of Abrocitinib for the Treatment of Mucous Membrane Pemphigoid: A Case Report
(Source: Patient Preference and Adherence)
Source: Patient Preference and Adherence - February 23, 2024 Category: International Medicine & Public Health Tags: Patient Preference and Adherence Source Type: research
Ocular cicatricial pemphigoid: is there an association with autoimmune diseases?
ConclusionsDue to OCP ’s autoimmune nature, it could coexist with other ADs. This study observed that more than a quarter of the population presented with this association, and hypergammaglobulinemia could suggest it. (Source: International Ophthalmology)
Source: International Ophthalmology - February 20, 2024 Category: Opthalmology Source Type: research
U-Serrated and N-Serrated Patterns in Bullous Pemphigoid, Epidermolysis Bullosa Acquisita, and Bullous Lupus: A Retrospective Observational Study
(Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - February 16, 2024 Category: Dermatology Authors: Catherine S. Barker, Evelyn Bruner, Sally Self, Dirk M. Elston Source Type: research
Laryngeal Manifestations of Bullous Pemphigoid: Case Report and Review of the Literature
Ear Nose Throat J. 2024 Feb 6:1455613241230252. doi: 10.1177/01455613241230252. Online ahead of print.ABSTRACTBullous pemphigoid (BP) is an autoimmune blistering disease that affects primarily the skin and rarely involves the mucosa of the oral cavity, larynx, pharynx, or esophagus. Diagnosis is based on the clinical presentation, histology, and immunopathological examination. Laryngeal involvement in BP is extremely rare and patients may be asymptomatic or may present with dysphonia, dysphagia, and/or respiratory distress. The authors of this article report a rare case of BP with laryngeal involvement with a review of the...
Source: Ear, Nose and Throat Journal - February 7, 2024 Category: ENT & OMF Authors: Abdul-Latif Hamdan Jonathan Abou Chaar Jihane Abou Rahal Source Type: research
A Novel Strategy for the Discovery of Drug Targets: Integrating Clinical Evidence with Molecular Studies
Biol Pharm Bull. 2024;47(2):345-349. doi: 10.1248/bpb.b23-00831.ABSTRACTThe mechanisms of several drugs remain unclear, limiting our understanding of how they exert their effects. Receptor affinities have not been comprehensively measured during drug development, and the safety investigations in humans are limited. Therefore, numerous unknown adverse and beneficial effects of drugs in humans persist. In this review, I highlight our achievements in identifying the unexpected beneficial effects of drugs through the analysis of real-world clinical data, which can contribute to drug repositioning and target finding. (1) Throug...
Source: Biological and Pharmaceutical Bulletin - January 31, 2024 Category: Drugs & Pharmacology Authors: Shuji Kaneko Source Type: research
Terbinafine induced bullous pemphigoid
Therapie. 2024 Jan 17:S0040-5957(24)00004-0. doi: 10.1016/j.therap.2023.12.005. Online ahead of print.NO ABSTRACTPMID:38290917 | DOI:10.1016/j.therap.2023.12.005 (Source: Therapie)
Source: Therapie - January 30, 2024 Category: Psychiatry & Psychology Authors: Khaoula Trimeche Ines Lahouel Nesrine Ben Salah Khadija Mansour Yosra Soua Ahlem Bellalah Zohra Chadly Hichem Belhadjali Jameleddine Zili Source Type: research
The Syk inhibitor entospletinib abolishes dermal-epidermal separation in a fully human ex vivo model of bullous pemphigoid
Bullous pemphigoid (BP) is an autoantibody-mediated blistering skin disease characterized by local inflammation and dermal-epidermal separation, with no approved targeted therapy. The Syk tyrosine kinase is critical for various functions of the immune response. Second-generation Syk inhibitors such as entospletinib are currently being tested for hematological malignancies. Our aim was to test the effect of entospletinib in a fully human model system of BP. Incubating BP serum-treated human frozen skin sections with normal human granulocytes and fresh plasma triggered dermal-epidermal separation which was dependent on compl...
Source: Journal of Investigative Dermatology - January 29, 2024 Category: Dermatology Authors: Simon Vik ár, Kata P. Szilveszter, Kamilla Koszorú, Miklós Sárdy, Attila Mócsai Tags: Original Article Source Type: research
